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CONSORT extension for the reporting of randomised controlled 
trials conducted using cohorts and routinely collected data 
(CONSORT-ROUTINE): checklist with explanation and elaboration
Linda Kwakkenbos,1 Mahrukh Imran,2 Stephen J McCall,3,4 Kimberly A McCord,5  
Ole Fröbert,6 Lars G Hemkens,5,7,8 Merrick Zwarenstein,9,10 Clare Relton,11 Danielle B Rice,2,12 
Sinéad M Langan,13 Eric I Benchimol,10,14,15 Lehana Thabane,16 Marion K Campbell,17  
Margaret Sampson,18 David Erlinge,19 Helena M Verkooijen,20,21 David Moher,22  
Isabelle Boutron,23,24 Philippe Ravaud,23,24 Jon Nicholl,25 Rudolf Uher,26 Maureen Sauvé,27,28 
John Fletcher,29 David Torgerson,30 Chris Gale,31 Edmund Juszczak,3,32 Brett D Thombs2,33
Randomised controlled trials are 
increasingly conducted as embedded, 
nested, or using cohorts or routinely 
collected data, including registries, 
electronic health records, and 
administrative databases, to assess if 
participants are eligible for the trial and 
to facilitate recruitment, to deliver an 
embedded intervention, to collect trial 
outcome data, or a combination of 
these purposes. This report presents 
the Consolidated Standards of 
Reporting Trials (CONSORT) extension 
for randomised controlled trials 
conducted using cohorts and routinely 
collected data (CONSORT-ROUTINE). 
The extension was developed to look at 
the unique characteristics of trials 
conducted with these types of data 
with the goal of improving reporting 
quality in the long term by setting 
standards early in the process of 
uptake of these trial designs. The 
extension was developed with a 
sequential approach, including a 
Delphi survey, a consensus meeting, 
and piloting of the checklist. The 
checklist was informed by the 
CONSORT 2010 statement and two 
reporting guidelines for observational 
studies, the Strengthening the 
Reporting of Observational Studies in 
Epidemiology (STROBE) statement and 
the REporting of studies Conducted 
using Observational Routinely 
collected Data (RECORD) statement. 
The extension includes eight items 
modified from the CONSORT 2010 
statement and five new items. 
Reporting items with explanations and 
examples are provided, including key 
aspects of trials conducted using 
cohorts or routinely collected data that 
require specific reporting 
considerations.
Well designed and conducted randomised controlled 
trials are the so called gold standard of healthcare 
intervention research.1-3 The use of reporting 
guidelines, including the Consolidated Standards 
of Reporting Trials (CONSORT) statement, improves 
the transparency and completeness of publications 
of the results of randomised controlled trials.4-7 The 
CONSORT 2010 statement facilitates critical appraisal 
and interpretation of randomised controlled trials 
by providing guidance to authors on a minimum set 
of items that should be reported for all trials.8 9 The 
aim of the CONSORT 2010 statement was to improve 
the reporting of two-arm parallel group randomised 
controlled trials. Extensions of the CONSORT statement 
have been developed to encourage better reporting of 
other trial designs, including, for example, multi-arm 
parallel group randomised trials,10 cluster trials,11 
pilot and feasibility trials,12 and pragmatic trials.13
Interest in randomised controlled trials conducted 
using cohorts14 or with routinely collected data 
is growing. Routinely collected data includes 
registries,15  16 electronic health records,17 and 
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SUMMARY POINTS
Trials might use a cohort or routinely collected data to identify eligible 
participants, to determine outcomes, to implement an intervention, or for a 
combination of these purposes.
These trial designs are relatively recent innovations, and published randomised 
controlled trial reports might not describe important aspects of their 
methodology in a standardised way.
A CONSORT extension was developed for the reporting of randomised controlled 
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administrative databases, such as government or 
private health insurance databases, social care 
databases, or education databases.18 In a cohort, a 
group of individuals is collected for the purpose of 
conducting research14 whereas routinely collected data 
refer to data initially collected for purposes other than 
research or without specific a priori research questions 
developed before collection.19 20 Trials might use a 
cohort or routinely collected data to identify eligible 
participants, to determine outcomes, to implement an 
intervention, or for a combination of these purposes. 
For example, in registry based randomised controlled 
trials, a registry could be used to identify eligible 
participants for a trial, for the collection of baseline 
characteristics of the participants, and as the source 
of outcome data; some registries have used interactive 
technology to actively flag participants to enrol in 
randomised controlled trials when patient data are 
entered into the registry.16 In some trials involving 
electronic health records, the electronic health 
record itself is used to implement an intervention. 
For example, one randomised controlled trial tested 
an intervention to reduce prescribing of antibiotics 
by feeding back personalised antibiotic prescription 
data to primary care physicians.21 Trials that use 
a cohort or routinely collected data to identify and 
recruit participants and to collect outcome data might 
be referred to as embedded or nested, whereas others 
might use the cohort or routinely collected data for one 
purpose or the other.
The use of cohorts and routinely collected data 
might make randomised controlled trials easier and 
more feasible to perform by reducing cost, time, and 
other resources, and could facilitate the conduct of 
trials that more closely replicate real world clinical 
practice by supporting recruitment of large and 
representative samples.22 23 These trial designs, 
however, are relatively recent innovations, and 
published randomised controlled trial reports might 
not describe important aspects of their methodology 
in a standardised way. Trials conducted using cohorts 
and routinely collected data share certain elements 
with conventional randomised controlled trials, but 
distinctive elements to report also exist, which are 
not covered in the CONSORT 2010 statement (box 
1).8 9 Because of the substantial overlap in the design, 
conduct, analysis, and reporting of trials conducted in 
cohorts and with different types of routinely collected 
data, we developed one CONSORT extension for the 
reporting of randomised controlled trials conducted 
using cohorts and routinely collected data (CONSORT-
ROUTINE).
Development and scope of the CONSORT extension
The project was registered with the Enhancing 
the QUAlity and Transparency Of health Research 
(EQUATOR) Network,24 and a protocol was published.23 
The extension was developed after a consensus driven 
process25 and included: confirmation of the need 
for a reporting guideline; a scoping review to assess 
reporting quality and identify reporting considerations 
to include in a preliminary checklist version26; a 
three round Delphi process to collect input on the 
checklist items from stakeholders, including reporting 
guideline developers, funders, journal editors, patient 
representatives, trial methodologists, epidemiologists, 
meta-research authors, ethicists, biostatisticians, 
and clinical trialists who were identified by members 
of the project team; a consensus meeting to advise 
on items to include and the checklist structure; and 
publication, dissemination, and implementation of 
the final checklist. Details on methods and results from 
each stage of the process are described elsewhere.27 
In brief, 27 items for consideration were initially 
developed by members of the CONSORT Extension 
Project Team based on review of items included in the 
CONSORT 2010 statement,8 9 the Strengthening the 
Reporting of Observational Studies in Epidemiology 
(STROBE)28 statement, and the REporting of studies 
Conducted using Observational Routinely collected 
Data (RECORD)29 statement, and also discussions with 
steering committee members. All items were rated 
in Delphi round 1. In Delphi round 2, 13 items were 
rated, and in round 3, 11 items were rated. Response 
rates for the Delphi study were 92 of 125 (74%) invited 
participants in round 1, 77 of 92 (84%) participants 
who completed round 1 in round 2, and 62 of 77 
(81%) participants who completed round 2 in round 
3. Members of the project team attended an in-person 
consensus meeting where the Delphi results were 
considered and a preliminary checklist was developed. 
The preliminary version of the checklist was pilot 
tested by 17 people with experience in trials conducted 
using cohorts or routinely collected data. In all stages 
of development, key stakeholders in trials research and 
potential end users of the CONSORT extension were 
involved, including participants from a wide range of 
scientific disciplines and with diverse experience in 
conducting trials in cohorts and with different types of 
routinely collected databases.
Consistent with other CONSORT statements, this 
extension describes a minimum set of information that 
should be reported and provides a checklist to facilitate 
compliance. The extension applies to randomised 
controlled trials conducted using one or more cohorts 
or routinely collected databases to: identify, recruit, 
or consent eligible participants; implement an 
intervention; collect trial data, including outcomes; 
or a combination of these purposes. For randomised 
controlled trials that use cohorts or routinely collected 
data to only assess outcomes, some extension items 
might not be relevant.
The extension includes eight items from the 
CONSORT 2010 statement that were modified and five 
new items. No items were removed from the CONSORT 
2010 checklist. Table 1 shows the extension items 
compared with the CONSORT 2010 checklist. Table 2 is 
the integrated extension checklist. Box 2 summarises 
important changes to the CONSORT 2010 statement.
For each modified and new item, this document 
describes the item, identifies whether the item was 
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explains the rationale for including the item, and 
elaborates on reporting considerations. For items that 
were not modified from the CONSORT 2010 statement, 
but for which reporting considerations exist for trials 
conducted using cohorts or routinely collected data, 
we have also provided an example and explanation. 
Examples of good reporting were retrieved from 
primary and secondary trial reports and, in some 
cases, trial protocols. For all items, the explanations 
provided supplement those in the CONSORT 2010 
explanation and elaboration statement.8 9 Adequate 
reporting of many trials conducted using cohorts or 
routinely collected data will also require reference to 
other CONSORT extensions (www.consort-statement.
org/extensions), including those for cluster trials,11 
pragmatic trials,13 and others. The CONSORT-ROUTINE 
explanation and elaboration statement only deals with 
reporting issues relevant to the use of cohorts and 
routinely collected data in trial design and conduct, 
and readers should consult other relevant extensions.
Title and abstract
Item 1a (unmodified)
Identification as a randomised trial in the title.
Examples
“Bivalirudin versus heparin in non-ST and ST-segment 
elevation myocardial infarction-a registry-based 
randomized clinical trial in the SWEDEHEART registry 
(the VALIDATE-SWEDEHEART trial).”30
“Clinical effectiveness and cost-effectiveness of a 
multifaceted podiatry intervention for falls preven-
tion in older people: a multicentre cohort randomised 
controlled trial (the REducing Falls with ORthoses and 
a Multifaceted podiatry intervention trial).”31
Explanation
Item 1a is meant to aid in indexing and identifying 
randomised controlled trial reports in electronic 
databases. The title, at a minimum, should contain 
recognisable terminology identifying the study as 
a randomised trial. If word count permits, the type 
of trial (eg, cohort multiple randomised controlled 
trials, registry based randomised controlled trials) or 
the cohort or routinely collected database(s) used to 
conduct the trial (eg, SWEDEHEART registry) should 
be provided.
Item 1b (modified)
CONSORT 2010 item: Structured summary of trial 
design, methods, results, and conclusions (for specific 
guidance see CONSORT for abstracts).
Modified CONSORT extension item: Structured 
summary of trial design, methods, results, and 
conclusions (for specific guidance see CONSORT for 
abstracts). Specify that a cohort or routinely collected 
data were used to conduct the trial and, if applicable, 
provide the name of the cohort or routinely collected 
database(s).
Examples
“The TIMING study is a national, investigator-led, 
registry-based, multicentre, open-label, randomised 
controlled study. The Swedish Stroke Register is used 
for enrolment, randomisation and follow-up.”32
“The Department of Veterans Affairs (VA) MI-
Plus study was a cluster-randomized trial involving 
Box 1: Key methodological issues and considerations in trials conducted using 
cohorts and routinely collected data
Design 
•	Trials conducted using cohorts or routinely collected databases might differ from 
conventional trial designs because they use these sources of data to identify 
eligible participants; automate randomisation; deliver an intervention; collect data, 
including assessing outcomes; or a combination of these functions.
•	Some trials might use a hybrid approach that integrates the use of these sources of 
data and trial specific methods for functions such as delivery of the intervention and 
assessing outcomes.
•	Cohorts and routinely collected databases can vary substantially in the way they 
represent complete, random, or convenience samples. Because the cohort or 
routinely collected database could serve as the sampling frame for the trial, the 
representativeness of participants in the trial might depend on the characteristics of 
the database.
•	The comprehensiveness, collection procedures, and type of demographic or 
outcome data available in a cohort or routinely collected database could influence 
the design of the trial, including the research question, eligibility criteria of the trial, 
and the choice of outcomes.
•	The timing between identifying eligibility, delivering the intervention, and assessing 
the outcomes might be governed by the frequency of data collection in a cohort or 
routinely collected database, and is less controllable by trial investigators than in 
conventional trials.
•	In trials using cohorts or routinely collected data, informed consent could be applied 
at different levels and in different ways compared with conventional trial designs. 
Consent might be sought and obtained to use the cohort or routinely collected 
database and for the trial, and consent that would typically be expected to occur in 
conventional trials might not be done because of features of the integrated cohort or 
database and trial design.
Conduct
•	Because cohorts, registries, electronic health records, and administrative 
databases vary in the way they are set up for research, clinical care, or financial 
and administrative purposes, the completeness and accuracy of the data might 
vary substantially between different databases and between variables within one 
database.
•	Challenges could arise in linking routinely collected data to other sources of data, 
including linkage errors when records cannot be linked or are linked incorrectly.
Analysis
•	A unique feature of trials using cohorts and routinely collected data is that 
investigators can often access information on participants not enrolled in the trial. 
Differences in baseline characteristics of eligible people from the cohort or routinely 
collected database who do not participate in the trial can often be compared with 
trial participants to inform judgments on the representativeness of the participants 
in the trial and the generalisability of the results.
Interpretation
•	Potential differences between the trial target population, people included in the 
cohort or routinely collected database, and participants in the trial, can influence 
the applicability of the trial results and should be considered when interpreting the 
findings.
•	Limitations to the use of a cohort or routinely collected data for a trial include 
constraints on available outcome measures and issues with data linkage, data 
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Section/topic
Item 
No CONSORT 2010 checklist item Extension for trials conducted using cohorts or routinely collected data
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results,  
and conclusions (for specific guidance  
see CONSORT for abstracts)
Structured summary of trial design, methods, results, and conclusions (for 
specific guidance see CONSORT for abstracts). Specify that a cohort or routinely 
collected data were used to conduct the trial and, if applicable, provide the  
name of the cohort or routinely collected database(s) (modified)
Introduction
Background and  
objectives
2a Scientific background and explanation of rationale —
2b Specific objectives or hypotheses —
Methods
Trial design 3a Description of trial design (such as parallel, factorial)  
including allocation ratio
Description of trial design (such as parallel, factorial) including allocation ratio, 
that a cohort or routinely collected database(s) was used to conduct the trial 
(such as electronic health record, registry) and how the data were used within 
the trial (such as identification of eligible trial participants, trial outcomes) 
(modified)
3b Important changes to methods after trial  
commencement (such as eligibility criteria), with 
reasons
—
Cohort or routinely 
collected database  
(new section heading)
ROUTINE-1 — Name, if applicable, and description of the cohort or routinely collected  
database(s) used to conduct the trial, including information on the setting  
(such as primary care), locations, and dates (such as periods of recruitment, 
follow-up, and data collection) (new)
ROUTINE-2 — Eligibility criteria for participants in the cohort or routinely collected database(s) 
(new)
ROUTINE-3 State whether the study included person-level, institutional-level, or other data 
linkage across two or more databases and, if so, linkage techniques and meth-
ods used to evaluate completeness and accuracy of linkage (new)
Trial participants  
(modified from  
“Participants”)
4a Eligibility criteria for participants Eligibility criteria for trial participants, including information on how to access 
the list of codes and algorithms used to identify eligible participants, information 
on accuracy and completeness of data used to ascertain eligibility, and methods 
used to validate accuracy and completeness (eg, monitoring, adjudication), if 
applicable (modified)
4b Settings and locations where the data were collected —
ROUTINE-4 — Describe whether and how consent was obtained (new)
Interventions 5 The interventions for each group with sufficient  
details to allow replication, including how and when  
they were actually administered
—
Outcomes 6a Completely defined pre-specified primary and  
secondary outcome measures, including how  
and when they were assessed
Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were ascertained and the cohort or routinely 
collected database(s) used to ascertain each outcome (modified)
ROUTINE-5 — Information on how to access the list of codes and algorithms used to define or 
derive the outcomes from the cohort or routinely collected database(s) used to 
conduct the trial, information on accuracy and completeness of outcome  
variables, and methods used to validate accuracy and completeness  
(eg, monitoring, adjudication), if applicable (new)
6b Any changes to trial outcomes after the trial  
commenced, with reasons
—
Sample size 7a How sample size was determined —
7b When applicable, explanation of any interim  




8a Method used to generate the random  
allocation sequence
—
8b Type of randomisation; details of any restriction  





9 Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence 
until interventions were assigned
Mechanism used to implement the random allocation sequence (such as 
embedding an automated randomiser within the cohort or routinely collected 
database(s)), describing any steps taken to conceal the sequence until  
interventions were assigned (modified)
Implementation 10 Who generated the random allocation sequence,  
who enrolled participants, and who assigned  
participants to interventions
—
Blinding 11a If done, who was blinded after assignment to  
interventions (for example, participants,  
care providers, those assessing outcomes) and how
—
11b If relevant, description of the similarity of interventions —
Statistical methods 12a Statistical methods used to compare groups  
for primary and secondary outcomes
—
12b Methods for additional analyses, such  
as subgroup analyses and adjusted analyses
—
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168 community-based primary care clinics and 847 
providers in 26 states, the Virgin Islands, and Puerto 
Rico with the clinic as the randomization unit. We 
collected administrative data for 15,847 post-MI 
[myocardial infarction] patients and medical record 
data for 10,452 of these.”33
Explanation
Abstracts are used for electronic database indexing 
and are the most commonly read sections of articles.9 34 
They provide information on the trial methodology 
and main results, and allow readers to evaluate if the 
study likely covers their information needs. In addition 
to CONSORT 2010 abstract elements, abstracts of 
trials using cohorts or routinely collected databases 
should clearly describe the type of cohort or routinely 
collected database used (eg, registry based trial), 
according to the examples above. The name of the 
cohort or database(s) used should also be reported, 
if applicable. Some databases, such as electronic 
health records, are typically unnamed, in which case 
stating that an electronic health record was used is 
enough. Ideally, the abstract will clarify the purpose 
for which the cohort or routinely collected database 
was used (eg, to identify eligible participants, to 
assess outcomes). More information related to the use 
of cohorts or routinely collected data that should be 
reported might also exist, depending on the specific 
trial design. Whenever possible, authors should report 




Scientific background and explanation of rationale 
(see CONSORT 2010).8 9
Item 2b (unmodified)





CONSORT 2010 item: Description of trial design (such 
as parallel, factorial) including allocation ratio.
Table 1 | Continued
Section/topic
Item 
No CONSORT 2010 checklist item Extension for trials conducted using cohorts or routinely collected data
Results
Participant flow  
(diagram is strongly 
recommended)
13a For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and 
were analysed for the primary outcome
For each group, the number of participants in the cohort or routinely collected 
database(s) used to conduct the trial and the numbers screened for eligibility, 
randomly assigned, offered and accepted interventions (eg, cohort multiple 
RCTs), received intended treatment, and analysed for the primary outcome 
(modified)
13b For each group, losses and exclusions after  
randomisation, together with reasons
—
Recruitment 14a Dates defining the periods of recruitment and follow-up —
14b Why the trial ended or was stopped —
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group
—
Numbers analysed 16 For each group, number of participants (denominator) 
included in each analysis and whether the analysis was 
by original assigned groups
—
Outcomes and  
estimation
17a For each primary and secondary outcome, results 
for each group, and the estimated effect size and its 
precision (such as 95% confidence interval)
—
17b For binary outcomes, presentation of both absolute 
and relative effect sizes is recommended
—
Ancillary analyses 18 Results of any other analyses performed, including  
subgroup analyses and adjusted analyses,  
distinguishing pre-specified from exploratory
—
Harms 19 All important harms or unintended effects in each 
group (for specific guidance see CONSORT for harms)
—
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses
—
Generalisability 21 Generalisability (external validity, applicability) of the 
trial findings
—
Interpretation 22 Interpretation consistent with results, balancing  
benefits and harms, and considering other  
relevant evidence
Interpretation consistent with results, balancing benefits and harms, and  
considering other relevant evidence, including the implications of using data  
that were not collected to answer the trial research questions (modified)
Other information
Registration 23 Registration number and name of trial registry —
Protocol 24 Where the full trial protocol can be  
accessed, if available
—
Funding 25 Sources of funding and other support (such as supply 
of drugs), role of funders
Sources of funding and other support for both the trial and the cohort or  
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Table 2 | Combined CONSORT 2010 and CONSORT-ROUTINE checklist
Section/topic
Item 




1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts). Specify 
that a cohort or routinely collected data were used to conduct the trial and, if applicable, provide the name of the cohort or 
routinely collected database(s)
Introduction
Background and  
objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio, that a cohort or routinely collected database(s) 
was used to conduct the trial (such as electronic health record, registry) and how the data were used within the trial (such as 
identification of eligible trial participants, trial outcomes)
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
Cohort or routinely  
collected database
ROUTINE-1 Name, if applicable, and description of the cohort or routinely collected database(s) used to conduct the trial, including information 
on the setting (such as primary care), locations, and dates (such as periods of recruitment, follow-up, and data collection)
ROUTINE-2 Eligibility criteria for participants in the cohort or routinely collected database(s)
ROUTINE-3 State whether the study included person-level, institutional-level, or other data linkage across two or more databases and, if so, 
linkage techniques and methods used to evaluate completeness and accuracy of linkage
Trial participants 4a Eligibility criteria for trial participants, including information on how to access the list of codes and algorithms used to identify 
eligible participants, information on accuracy and completeness of data used to ascertain eligibility, and methods used to 
validate accuracy and completeness (eg, monitoring, adjudication), if applicable
4b Settings and locations where the data were collected
ROUTINE-4 Describe whether and how consent was obtained
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were  
actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were ascertained 
and the cohort or routinely collected database(s) used to ascertain each outcome
ROUTINE-5 Information on how to access the list of codes and algorithms used to define or derive the outcomes from the cohort or routinely 
collected database(s) used to conduct the trial, information on accuracy and completeness of outcome variables, and methods 
used to validate accuracy and completeness (eg, monitoring, adjudication), if applicable
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping guidelines
Sequence  
generation
8a Method used to generate the random allocation sequence




9 Mechanism used to implement the random allocation sequence (such as embedding an automated randomiser within the 
cohort or routinely collected database(s)), describing any steps taken to conceal the sequence until  
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing  
outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant flow  
(a diagram is  
strongly  
recommended)
13a For each group, the number of participants in the cohort or routinely collected database(s) used to conduct the trial and the 
numbers screened for eligibility, randomly assigned, offered and accepted interventions (eg, cohort multiple RCTs), received 
intended treatment, and analysed for the primary outcome
13b For each group, losses and exclusions after randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original 
assigned groups
Outcomes and  
estimation
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision  
(such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre- 
specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence, including the 
implications of using data that were not collected to answer the trial research questions
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support for both the trial and the cohort or routinely collected database(s), role of funders
RCT=randomised controlled trial.


























































































ReseaRch Methods and RepoRting
the bmj | BMJ 2021;373:n857 | doi: 10.1136/bmj.n857 7
Modified CONSORT extension item: Description 
of trial design (such as parallel, factorial) including 
allocation ratio, that a cohort or routinely collected 
database(s) was used to conduct the trial (such as 
electronic health record, registry) and how the data 
were used within the trial (such as identification of 
eligible trial participants, trial outcomes).
Examples
“The Determination of the Role of Oxygen in Suspected 
Acute Myocardial Infarction (DETO2X-AMI) trial was 
a multicenter, parallel-group, open-label, registry-
based, randomized, controlled trial in which routine 
supplemental oxygen therapy was compared with 
ambient air in the treatment of patients with suspected 
myocardial infarction who did not have hypoxemia at 
baseline. The trial used the national comprehensive 
Swedish Web System for Enhancement and 
Development of Evidence-Based Care in Heart Disease 
Evaluated According to Recommended Therapies 
(SWEDEHEART) for patient enrollment and data 
collection.”35
“PATIENT was a parallel arm, pragmatic clinical 
trial in which 21,752 adults were randomized to 
receive either UC [usual care] or 1 of 2 interventions 
designed to increase adherence to statins, angiotensin-
converting enzyme inhibitors (ACEIs), and angiotensin 
receptor blockers (ARBs) Using each region’s EMR 
[electronic medical record], we identified participants 
40 years and older with diabetes mellitus and/or 
cardiovascular disease (CVD), suboptimally (<90%) 
adherent to a statin or ACEI/ARB during the previous 
12 months, and due or overdue for a refill Within each 
region, we randomly assigned a sample of eligible 
members to the 3 primary study arms (usual care 
and 2 intervention arms) in a 1:1:1 ratio at the study 
outset We used the EMR to capture age, race, gender, 
healthcare utilization for diabetes and CVD, and BP 
[blood pressure] and lipid levels.”36
Explanation
According to CONSORT 2010, authors should describe 
the trial design (eg, parallel group, cluster randomised), 
conceptual framework (eg, superiority, equivalence, 
or non-inferiority), and allocation ratio (eg, 1:1, 2:1). 
Also, they should describe that one or more cohorts or 
routinely collected databases were used, how they were 
used (eg, to identify eligible participants, to deliver 
the intervention, to collect data including to assess 
outcomes), and whether their use influenced other 
methodological choices that might have implications 
for how the results of the trial are interpreted and apply 
to different populations. Examples include constraints 
on the eligibility criteria for the trial; timing between 
evaluating eligibility, delivery of the intervention, and 
assessing outcomes; and outcomes available.
Item 3b (unmodified)
Important changes to methods after trial commence-
ment (such as eligibility criteria), with reasons (see 
CONSORT 2010).8 9
Trial methods and procedures might depend on 
protocols (eg, eligibility criteria, outcomes assessed 
of cohorts or routinely collected databases). Changes 
to protocols that affect aspects of trial methods, such 
as identification of eligible participants, outcome 
variables collected, or timing of outcome assessments, 
should be described (see also ROUTINE-1 and 
ROUTINE-2).
Cohort or routinely collected database (new section 
subheading)
Item ROUTINE-1 (new)
Name, if applicable, and description of the cohort or 
routinely collected database(s) used to conduct the 
trial, including information on the setting (such as 
primary care), locations, and dates (such as periods of 
recruitment, follow-up, and data collection).
Examples
“Family practices in England, Scotland, or Wales were 
eligible for the study if they were contributing data 
to the Clinical Practice Research Datalink (CPRD). 
The CPRD is a large database that includes the EHRs 
[electronic health records] of ≈ 7% of all UK general 
practices from 1987 to the present.”37
“The [Scleroderma Patient-centered Intervention 
Network] SPIN Cohort is a convenience sample. 
Eligible SPIN Cohort patients are recruited at SPIN 
sites (https://www.spinsclero.com/en/sites) during 
regular medical visits, and written informed consent 
is obtained. A medical data form is submitted online 
by the site to enrol participants. Cohort participants 
complete outcome measures via the internet upon 
enrolment and subsequently every 3 months. SPIN 
Cohort enrollment started in March 2014 and is 
ongoing.”38
Box 2: Summary of major changes to the CONSORT 2010 statement
New items—introduces five new items that are specific to randomised controlled trials 
conducted using cohorts or routinely collected data
•	ROUTINE-1 on the description of the cohort or routinely collected database(s)
•	ROUTINE-2 on the eligibility criteria for participants in the cohort or routinely 
collected database(s)
•	ROUTINE-3 on data linkage across two or more databases
•	ROUTINE-4 on consent for use of cohort or routinely collected data and trial 
participation
•	ROUTINE-5 on codes and algorithms used to define or derive the outcomes from the 
cohort or routinely collected database(s)
Modified items—modifies eight CONSORT 2010 items
•	Item 1b on specifying that a cohort or routinely collected data were used in the 
abstract
•	Item 3a on specifying that a cohort or routinely collected data were used in the trial 
design
•	Item 4a on eligibility criteria for trial participants
•	Item 6a on outcome measures
•	Item 9 on implementation of the random allocation sequence
•	Item 13a on the participant flow
•	Item 22 on the interpretation of results
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Explanation
This new section covers a wider description of the 
cohort or routinely collected database that is different 
from the description of how the cohort or database 
was used in the trial, which is covered in section 4 
(trial participants). Providing the name of the cohort or 
routinely collected database allows readers to identify 
other studies, including trials, conducted with the 
same cohort or database and consider if the results 
apply to their setting. A description of the cohort or 
routinely collected database, including geographical 
locations and clinical settings, enables readers to 
assess characteristics relevant to understanding 
the sampling frame for recruitment of participants 
to the trial and the potential validity of the data for 
the research question. The authors should provide 
references to any publications that have described the 
cohort or database methods, or characteristics of the 
included participants. A rationale for why the specific 
cohort or routinely collected database was used for the 
trial should be provided.
Characteristics that could influence data quality 
should be reported and, if applicable, include 
the reason for data collection (eg, clinical care, 
administrative purposes), and the time period and 
related procedures by which data are collected, 
among others. Information on surgical procedures, 
for example, might be complete and accurate for 
administrative data derived from physician billing 
because reimbursement depends on its accuracy. 
Associated diagnostic codes, however, might be less 
reliable if these codes are not essential for billing. For 
data collected with electronic health records in the 
UK, for example, data that relate to items detailed in 
the Quality Outcomes Framework are likely of better 
quality if captured after 2004.39 Any changes in cohort 
or routinely collected database procedures, such as 
frequency of data collection or items collected, could 
lead to changes in outcome variables in randomised 
controlled trials or other aspects of trial conduct and 
should be reported.
Item ROUTINE-2 (new)
Eligibility criteria for participants in the cohort or 
routinely collected database(s).
Examples
“Patients were eligible for inclusion in the cohort if 
they were 45 years or older; had a smoking history of at 
least 10 pack-years; had a clinical diagnosis of mild-to-
severe COPD [chronic obstructive pulmonary disease], 
defined as a postbronchodilator forced expiratory 
volume in 1s (FEV1) to forced vital capacity ratio of 0.7 
or lower and a postbronchodilator FEV1 of at least 30%, 
according to Global Initiative of Chronic Obstructive 
Lung Disease (GOLD) and American Thoracic Society 
and European Respiratory Society criteria (GOLD 
stage 1–3); and had at least one documented or self-
reported exacerbation during the past 3 years, with the 
restriction that the last exacerbation had ended at least 
4 weeks before inclusion and symptoms had returned 
to patients’ baseline levels. Exclusion criteria were 
poor mastery of the Dutch language, poor cognitive 
functioning, known allergy to doxycycline, pregnancy, 
and a life expectancy of shorter than 1 month.”40
“Baseline characteristics and clinical outcomes 
will be extracted from routinely recorded clinical 
data held in the NNRD [National Neonatal Research 
Database]. The NNRD holds data from all infants 
admitted to National Health Service (NHS) neonatal 
units in England, Scotland and Wales (~90 000 infants 
annually). Contributing neonatal units are known 
as the UK Neonatal Collaborative. Data are extracted 
from point-of-care neonatal electronic health records 
completed by health professionals during routine 
clinical care. A defined data extract, the Neonatal 
Dataset of ~450 data items, is transmitted quarterly 
to the Neonatal Data Analysis Unit at Imperial College 
London and Chelsea and Westminster NHS Foundation 
Trust where patient episodes across different hospitals 
are linked and data are cleaned (queries about 
discrepancies and implausible data configurations are 
fed back to health professionals and rectified).”41
Explanation
Because the cohort or routinely collected database 
serves as the sampling frame for the trial, the 
representativeness of the participants in the trial 
depends on the eligibility criteria, and a clear 
description of criteria for entry into the cohort or 
routinely collected database should be provided.29 
For example, in health administrative data, having 
insurance (eg, Medicare in the United States) is a 
prerequisite for having a record in the database; a 
randomised controlled trial with participants recruited 
from the database could only be representative of 
people with insurance coverage.
When a cohort or routinely collected database in 
which eligibility fluctuates over time is used (eg, health 
insurance data), researchers should clearly specify how 
eligibility was defined and how changes in eligibility 
over the study period were managed. Also, changes in 
variable coding over time could result in differences 
in characteristics of participants considered eligible 
for enrolment in the randomised controlled trial. 
Therefore, coding changes relevant to characterising 
participants in the cohort or database, and eligibility 
criteria and enrolment in the randomised controlled 
trial, should be reported.
Item ROUTINE-3 (new)
State whether the study included person-level, 
institutional-level, or other data linkage across two 
or more databases and, if so, linkage techniques and 
methods used to evaluate completeness and accuracy 
of linkage.
Examples
[Information in main text] “Individuals on the 
Oregon Experiment “reservation list” (N=100 407) 
were probabilistically matched to individual OCHIN 


























































































ReseaRch Methods and RepoRting
the bmj | BMJ 2021;373:n857 | doi: 10.1136/bmj.n857 9
patients (N=106 692), using Link Plus software and 
demographic variables common to both data sets. 
Two researchers independently performed a case-by-
case review of uncertain matches using additional 
demographic variables. Appendix Table 1 provides 
more details.”
[Information in appendix] “To identify individuals 
common to both the Medicaid reservation list and the 
OCHIN patient population, we used Link Plus software 
to probabilistically compare demographic variables 
contained in both datasets. Matching variables 
included first and last name, date of birth, gender, street 
address, city, Oregon Medicaid identification number, 
and preferred language. The software generates a 
“match score” indicating each pair’s likelihood of 
being a match. For pairs of uncertain match status 
based on match score, we conducted double clerical 
review by independent reviewers. We also completed 
several rounds of quality assurance analyses to verify 
the validity of our match results.”42
Explanation
When databases are linked, investigators need to 
select a set of variables to use for linking, determine 
the best method for linking the databases and develop 
a linking algorithm, and evaluate the accuracy of 
linkages between the databases.43 A description 
of linkage methods and the success of linkage is 
critical to allow the reader to assess the likelihood 
and potential effect of any linkage error and the 
possibility of related bias.44 Linkage bias occurs when 
associations are present between the probability of 
linkage error (eg, false and missing matches) and 
variables of interest. For example, linkage rates 
might vary by patient characteristics, such as health 
status or health services received. Even small errors 
in the linkage process can introduce bias and lead to 
results that can overestimate or underestimate the 
associations being studied.45
Authors should describe if linkage of records 
across multiple databases was conducted and, 
if so, the methods of linkage (eg, deterministic v 
probabilistic, quality and type of variables used for 
linkage), how linkage validation was done, and the 
results of linkage validation with estimated rates of 
successful linkage. Details should be provided on 
blocking variables (variables used to form pairs for 
comparison only among those with the potential to 
be matches, such as the first three digits of a postal 
code), completeness of linkage variables, linkage 
rules, thresholds, and manual review of potential 
matches, if undertaken.46 47 If linkage was conducted 
before the trial for previous studies or general use, or 
if linkage was undertaken by an external provider, 
such as a data linkage centre, a reference describing 
the data resource and linkage methods should be 
provided. Authors should report linkage error with 
standard approaches including comparisons with 
gold standards or reference datasets, sensitivity 
analyses, and comparing characteristics of linked and 
unlinked data.48
Trial participants (modified section subheading)
Item 4a (modified)
CONSORT 2010 item: Eligibility criteria for participants.
Modified CONSORT extension item: Eligibility criteria 
for trial participants, including information on how to 
access the list of codes and algorithms used to identify 
eligible participants, information on accuracy and 
completeness of data used to ascertain eligibility, and 
methods used to validate accuracy and completeness 
(eg, monitoring, adjudication), if applicable.
Examples
“Primary care physicians were eligible for the study 
if they practiced in a study clinic, provided care to 
at least 10 adults with type 2 diabetes, and provided 
written informed consent to participate. Patients were 
classified as having diabetes if they had 2 or more 
out-patient diabetes International Classification of 
Diseases, Ninth Revision (ICD-9) codes (250.xx) or 
used 1 or more diabetes-specific medications in the 
1-year period before randomization. This diabetes 
identification method has estimated sensitivity of 0.91 
and positive predictive value of 0.94.”49
“An EHR [electronic health record]-based algorithm 
to identify eligible patients was constructed based on 
International Classification of Diseases, 9th and 10th 
Revisions, Clinical Modification codes (67–69) (see 
Table E1 in the online supplement) that are present 
on admission. In addition, nurses complete a five-
item electronic checklist during intake to denote the 
disease-specific eligibility criteria. To validate the 
algorithm, we reviewed 271 medical charts across 
the participating hospitals. The algorithm identified 
171 of these patients as eligible and 100 as ineligible. 
Using manual chart review as the gold standard, the 
algorithm had a false-positive rate of 1% and a false-
negative rate of 5%.”50
Explanation
This section relates to entry into the trial (rather than 
the cohort or routinely collected database, which is 
covered in items ROUTINE-1 to ROUTINE-3). When 
eligible trial participants were identified from records 
in a cohort or routinely collected database, authors 
should report information necessary to evaluate 
or replicate this process. This information should 
include a clear and detailed description of all codes, 
algorithms, and free text field entries, or combinations 
of these, including any statistical code if possible. 
Ideally, a link to all material needed for replication 
should be provided in an appendix or posting to an 
accessible website.
Use of routinely collected data could introduce 
some degree of misclassification bias, and information 
on the validity of participant classification must be 
specifically described, including reference to available 
validation studies and any methods used to directly 
assess the validity of the data used for classification 
of participants and the accuracy of the classification. 
Potential changes that could affect different settings 
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standards or strategies that might affect the validity of 
the data are changed, or when software or algorithms 
are updated).
To help readers assess the applicability of trial 
results, authors should clearly describe potential 
differences between the trial target population, people 
included in the cohort or health database, and actual 
participants in the trial. Filtering effects could occur, 
for instance, when data are more often incomplete in 
special situations, such as emergency visits (compared 
with routine visits) as a result of different processes for 
routine data collection, and if people with incomplete 
data are not screened for trial eligibility.
Item 4b (unmodified)
Settings and locations where the data were collected.
Examples
“The trial was conducted in the area of the Lille-Douai 
Health Insurance district (Northern France) during the 
institutional seasonal influenza vaccination campaign 
of 2014–2015. In the intervention group, 25 GPs 
received and were supposed to expose in their waiting 
rooms 135 pamphlets and one poster (added to the 
usual mandatory information) withdrawing all the 
other posters. In the control group, waiting rooms were 
kept in their usual state. Data were extracted between 
October 15, 2014 and February 28, 2015 from the 
SIAM-ERASME claim database of the Lille-Douai 
district Health Insurance Fund on patient level.”51
“The present study is one of three trials that took 
place in the context of the PRO-AGE (PRevention in 
Older people-Assessment in GEneralists’ practices) 
project in three locations. The present study was 
conducted in Hamburg, Germany, and was intended 
to test whether HRA-O [health risk appraisal for older 
persons], combined with personal reinforcement and 
supplemented. In Hamburg, general practitioners 
(GPs) registered in the entire metropolitan area (~500 
GPs) were informed via the newsletter of their regio-
nal GP association (BDA-Landesverband Hamburg). 
Survival, nursing home admission, and need for 
ambulatory nursing care as well as change of residence 
data were obtained from the GP records and completed 
with participant and proxy information. At year 1, the 
HRA-O questionnaire was used for collecting outcome 
information from all study participants. It was sent 
to surviving persons in combination with a short 
questionnaire on self-efficacy in the patient–physician 
interaction.”52
Explanation
Information on the settings and locations where the 
trial was conducted is key to judge the applicability 
and generalisability of the trial.8 9 In trials conducted 
in cohorts or with routinely collected data, authors 
should describe where the trial was implemented 
and specify if differences existed between centres 
where overall cohort or database data were collected 
(see item ROUTINE-2) and those involved in the trial. 
This situation might occur if only a subset of centres 
in the cohort or database are selected randomly or by 
characteristics, such as the quality of the data, location, 
delivery of healthcare, or language. Also, centres in a 
cohort, for instance, could be assigned to participate in 
different ongoing trials occurring simultaneously or in 
overlapping time periods with the same cohort.
Item ROUTINE-4 (new)
Describe whether and how consent was obtained.
Example
“At enrollment in the cohort, patients are asked to 
provide informed consent for prospective collection 
of clinical, survival and PROMs [patient-reported 
outcome measures] data we ask patients’ consent to 
be randomly selected to receive offers on experimental 
interventions in the future and to use their data 
comparatively Patients within the cohort who meet 
the inclusion criteria form a subcohort of eligible 
patients From among this subcohort, a random 
sample is selected. Randomly selected patients are 
offered the experimental intervention (boost prior to 
sCRT [standardised chemoradiation therapy]) by their 
treating physician. If they accept the offer, they will sign 
an additional informed consent to receive the boost. 
Patients who refuse the boost will receive care as usual 
(that is, sCRT). Patients in the subcohort who will not 
be randomly selected will not be informed about the 
boost intervention, nor will they be informed about 
their participation in the control arm of this study.”53
Explanation
In trials in cohorts and with routinely collected data, 
informed consent might be applied at different levels 
and at multiple stages for an individual participant, 
and in different ways than in conventional randomised 
controlled trial designs where consent is usually 
obtained once for treatment, randomisation, and data 
use.54 Reporting the information provided to potential 
participants and the consent sought will help readers 
understand what participants knew and what they 
expected or hoped might happen at each stage of the 
research, including the trial. Clearly describing this 
information in the text and in flow diagrams will allow 
readers to evaluate the applicability of the trial results 
and facilitate replication.
Authors should describe the different types of 
consent sought and obtained for the cohort or routinely 
collected database, and the trial. These might include: 
consent for use of health data for research from a 
cohort or routinely collected database; consent to be 
contacted for future research purposes; prior consent 
to future randomisation without explicit notice, which 
often occurs in trials that use the cohort multiple 
randomised controlled trial design14 55; consent to 
receive a trial intervention; or conventional consent 
for participation in the trial and randomisation. 
Other types of consent could also be relevant, such 
as consent to no description of the experimental 
intervention if allocated to the control, or consent for 
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sought, authors should describe from whom consent 
was sought, whether consent was sought for all 
participants in the trial or only some (eg, only those 
allocated to a trial intervention), and when each type 
of consent was sought.
Interventions
Item 5 (unmodified)
The interventions for each group with sufficient details 
to allow replication, including how and when they 
were actually given.
Example
“We developed a computer-based electronic alert 
system for identifying consecutive hospitalized OAC 
[oral-anticoagulation]-naïve patients with AF [arterial 
fibrillation] and tested the hypothesis that such an 
alert system would improve OAC prescription. The 
alert system automatically identified hospitalized 
patients with AF without an active OAC prescription 
in the electronic order entry system. The alert system 
was incorporated into the electronic medical chart 
and order entry system of the University Hospital in 
Bern, Switzerland. It recognized AF by permanently 
searching diagnosis lists and physician notes of 
the entire electronic patient chart database for free 
text entries of AF or its various abbreviations. Alerts 
were issued 24 hours after the onset of hospital stay 
if 4 criteria for an individual patient were present 
Once the criteria were fulfilled, the alert was issued 
in the electronic patient chart. The alert was visible 
to physicians and nurses, but only physicians were 
enabled to respond to the alert.”56
“Intervention included a single real-time notifica-
tion by letter to the patient and by electronic message 
within the KPSC [Kaiser Permanente Southern 
California] electronic medical record system to each 
patient’s primary care provider and asthma specialist 
(if the patient had previously seen one). The patient 
letters and physician messages noted excessive SABA 
[short-acting β2-agonist] dispensing, suggestions 
for management, and facilitated allergy referral 
recommendation for those patients without prior 
asthma specialist care Controls received KPSC standard 
asthma care management without research contact.”57
Explanation
Interventions are sometimes delivered by electronic 
health record systems or with an administrative 
database. Examples provided here describe a clinical 
decision support tool56 and a drug alert system57 
embedded within electronic health records. Other 
examples could include reminders or links to a clinical 
practice guideline when specific disease codes or other 
patient characteristics (eg, age, sex) that indicate 
guideline relevance are entered into an electronic 
health record. Authors should report interventions 
triggered or delivered by an electronic health record, 
registry, or administrative database in enough detail so 
that readers can understand the characteristics of the 
intervention, replicate the intervention in other research, 
and implement the intervention clinically. The Template 
for Intervention Description and Replication (TIDieR) 
provides guidance for reporting of interventions.58
Outcomes
Item 6a (modified)
CONSORT 2010 item: Completely defined pre-specified 
primary and secondary outcome measures, including 
how and when they were assessed.
Modified CONSORT extension item: Completely 
defined pre-specified primary and secondary outcome 
measures, including how and when they were 
ascertained and the cohort or routinely collected 
database(s) used to ascertain each outcome.
Examples
“A hard CVD [cardiovascular disease] event, the 
primary outcome, was defined as the occurrence of 
any of the following events in the medical record or 
Medicare/Medicaid data between IMPACT [Improving 
Mood-Promoting Access to Collaborative Treatment] 
enrollment date and December 31, 2008: a) fatal MI 
[myocardial infarction] (International Classification of 
Diseases, 10th Revision codes I21-I22 the first-listed 
cause of death), b) laboratory evidence of acute MI 
(creatine kinase-myocardial band isoenzyme value 
93.0 ng/ml or troponin value 90.3 K g/l), c) acute MI 
diagnosis (ICD-9 code 410), d) fatal stroke (International 
Classification of Diseases, 10th Revision codes I60-I64 
the first-listed cause of death), or e) hemorrhagic (ICD-
9 codes 430Y432) or nonhemorrhagic (ICD-9 codes 
433.01, 433.11, 433.21, 433.31, 433.91, 434.01, 
434.11, and 434.91) stroke diagnosis. Secondary 
outcomes were fatal/nonfatal MI (categories a-c), fatal/
nonfatal MI-cardiac enzyme confirmed (categories a 
and b), fatal/nonfatal stroke (categories d and e), and 
all-cause mortality. Death dates were extracted from 
the Medicare data, and causes of death were obtained 
from death certificates provided by the Indiana State 
Department of Health Patients were followed up for 
a maximum of 7.5 to 9.5 years (median = 8.1 years); 
however, for cause of death (categories a and d), 
patients were followed up for a maximum of 5.5 to 7.5 
years (median = 6.2 years).”59
“The trial used the national comprehensive Swedish 
Web System for Enhancement and Development of 
Evidence-Based Care in Heart Disease Evaluated 
According to Recommended Therapies (SWEDEHEART) 
for patient enrollment and data collection The 
primary end point was death from any cause within 
365 days after randomization, assessed in the 
intention-to-treat population. Secondary end points 
included death from any cause within 30 days after 
randomization, rehospitalization with myocardial 
infarction, rehospitalization with heart failure, and 
cardiovascular death  as well as composites of these 
end points, assessed at 30 days and 365 days Data on 
the end points of rehospitalization with heart failure 
and cardiovascular death are not available from 
SWEDEHEART and must be obtained from the Swedish 
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data were obtained from the Swedish National 
Population Registry, which includes the vital status of 
all Swedish citizens. All other variables were obtained 
from SWEDEHEART, which is monitored on a regular 
basis. Diagnoses at discharge are listed according to 
codes from the International Classification of Diseases, 
10th Revision (ICD-10). The end of follow-up was 
December 30, 2016, which was 365 days after the 
last patient underwent randomization. To allow for 
any lag in registry reporting, the final database was 
extracted from SWEDEHEART on February 28, 2017, 
including data on any linked deaths that occurred 
through December 30, 2016, and reported in the 
population registry as of February 14, 2017 No central 
adjudication or trial-specific patient follow-up was 
performed.”35
Explanation
All primary and secondary outcomes should be 
identified and defined, including how and when they 
were measured, and the cohort(s) or routinely collected 
database(s) used to ascertain the outcome. The use 
of routinely collected data might introduce some 
degree of misclassification. Details on the accuracy 
and validity of outcome data (eg, classification of 
participants) must be described, including reference 
to available validation studies and any methods used 
to directly assess the validity of data used as primary 
or secondary outcomes and the accuracy of the data 
collected. If different databases are used in some 
sites in the trial, authors should note if outcomes are 
determined consistently across trial sites.
Because follow-up periods might be considerably 
longer than recruitment periods, sometimes lasting 
decades, special attention should be given to potential 
changes that occur over time that might affect the 
collection, quality, and completeness of the data. 
Authors could consider using flow diagrams or special 
tables to describe these circumstances. A crucial aspect 
to consider and carefully report is any connection 
between collection of outcomes and trial arms (eg, 
detection bias). For example, a comparison of surgery 
versus non-surgical care should consider that special 
diagnostic procedures that are routinely done in surgical 
follow-up visits might not be done in the control group.
Item ROUTINE-5 (new)
Information on how to access the list of codes and 
algorithms used to define or derive the outcomes from 
the cohort or routinely collected database(s) used 
to conduct the trial, information on accuracy and 
completeness of outcome variables, and methods used 
to validate accuracy and completeness (eg, monitoring, 
adjudication), if applicable.
Example—information on how to access list of codes 
and algorithms used to define or derive outcomes 
from cohort or routinely collected database(s) used 
to conduct the trial
“The primary outcomes were whether or not the 
patient received preventive care services in the post-
period: screenings for cervical, breast, and colorectal 
cancer (fecal occult blood testing and colonoscopy); 
screenings for diabetes (glucose and hemoglobin A1c 
[HbA1c]), hypertension, obesity, and smoking; lipid 
screening; chlamydia testing; and receipt of influenza 
vaccination. Codes were used based on EHR [electronic 
health record] Meaningful Use Stage 1 measures. 
These included ICD-9-CM [International Classification 
of Diseases, ninth revision, clinical modification] 
diagnosis and procedure codes, Current Procedural 
Terminology and Healthcare Common Procedure 
Coding System codes, Logical Observation Identifiers 
Names and Codes, and medication codes. The authors 
also used relevant code groupings and codes specific 
to the OCHIN [Oregon Community Health Information 
Network] EHR, used for Meaningful Use reporting and 
internal quality improvement initiatives. Appendix 
Table 2 provides detailed technical specifications 
and patient eligibility criteria for each measure 
(see https://ars.els-cdn.com/content/image/1-s2.0-
S0749379715004237-mmc1.pdf).”42
Examples—information on accuracy and 
completeness of outcome variables, and methods 
used to validate accuracy and completeness (eg, 
monitoring, adjudication)
[In supplement]“Uppsala Clinical Research Center 
provides manuals, education and technical advice, 
including a telephone help desk for all users of the 
registry. The system has error checking routines for 
range and consistency. Definitions are easily available 
when data are entered. To ensure the correctness of 
the data entered a monitor visits about 20 hospitals 
each year and compares data entered into the 
SWEDEHEART [Swedish Web System for Enhancement 
and Development of Evidence-Based Care in Heart 
Disease Evaluated According to Recommended 
Therapies] with the information in the patients’ 
records from 30–40 randomly chosen patients in each 
hospital. When 637 randomly chosen computer forms 
from 21 hospitals containing 38 121 variables were 
reviewed in 2007, there was a 96.1% (range: 92.6%-
97.4%) agreement.”60
“If a patient was suspected to have had a clinical 
end-point event (i.e., death, myocardial infarction, 
bleeding, or stroke), the patient’s health care records 
were subjected to central blinded adjudication 
to determine the cause of the event according to 
prespecified criteria.”61
Explanation
Trials using cohorts or routinely collected data might 
require specific codes or algorithms, such as diagnostic 
codes, to identify and define outcomes. An electronic 
health record query can be performed, for example, 
with a list of diagnostic codes to identify all patients 
who have experienced a specific adverse event. An 
algorithm, or sequence of steps necessary to score 
or grade an outcome, could also be used. To assess 
validity and to facilitate reproducibility, the list of 
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an external source within the text or in supplementary 
material, ideally with the computer code used to 
reproduce this step.
Cohorts and routinely collected data are often 
collected and entered by staff involved in routine 
patient care or by non-clinical staff, based on medical 
records, and the level of completeness varies. Also, 
procedures for entering data for clinical care or 
billing might introduce certain biases, and concerns 
about data completeness and accuracy could arise.62 
Authors should describe data completeness in enough 
detail so that others can evaluate accuracy. Issues 
of misclassification, and any efforts to minimise 
misclassification, should be reported.
Outcome definitions might vary between cohorts and 
routinely collected data, and standards commonly used 
in clinical trials and data fields might be missing. The 
authors should describe any adjudication of outcomes, 
if adjudication was blinded to trial allocation, and 
which outcome definitions were used (eg, by referring 
to a separate adjudication protocol).
Item 6b (unmodified)
Any changes to trial outcomes after the trial 
commenced, with reasons (see CONSORT 2010).8 9
Sample size
Item 7a (unmodified)
How sample size was determined (see CONSORT 
2010).8 9
Item 7b (unmodified)
When applicable, explanation of any interim analyses 
and stopping guidelines (see CONSORT 2010).8 9
Randomisation
Item 8a (unmodified)
Method used to generate the random allocation 
sequence (see CONSORT 2010).8 9
Item 8b (unmodified)
Type of randomisation; details of any restrictions (such 
as blocking and block size; see CONSORT 2010).8 9
Allocation concealment mechanism
Item 9 (modified)
CONSORT 2010 item: Mechanism used to implement 
the random allocation sequence (such as sequentially 
num bered containers), describing any steps taken 
to con-ceal the sequence until interventions were 
assigned.
Modified CONSORT extension item: Mechanism 
used to implement the random allocation sequence 
(such as embedding the random allocation sequence 
within the cohort or routinely collected database(s)), 
describing any steps taken to conceal the sequence 
until interventions were assigned.
Examples
“The [WithHolding Enteral feeds Around packed red cell 
Transfusion] WHEAT trial is a randomised controlled, 
unblinded, multicentre, pilot trial comparing two 
care pathways. Infants will be randomised with a 1:1 
allocation ratio (using permuted blocks of variable 
size), stratified within neonatal unit by gestational age 
at birth and infant sex. Trial processes will be embedded 
within neonatal EPR [electronic patient record] systems 
and all outcome data will be extracted from data that 
are routinely recorded within the existing neonatal 
EPR systems (BadgerNet and BadgerEPR), and held 
in the NNRD [National Neonatal Research Database]. 
Infants will be randomised using an online secure 
central randomisation system which will be embedded 
into the existing neonatal EPR systems (BadgerNet and 
BadgerEPR). Randomisation will occur within the EPR 
to ensure allocation concealment.”41
“Randomization to be offered versus not offered, 
the SPIN-HAND [Scleroderma Patient-centered Inter-
vention Network hand exercise program] intervention 
will occur at the time of Cohort participants’ regular 
SPIN Cohort assessments. Eligible Cohort participants, 
based on questionnaire responses, will be randomized 
automatically as they complete their regular SPIN 
Cohort assessments using a feature in the SPIN Cohort 
platform, which provides immediate centralized rando-
mization and, thus, complete allocation sequence 
concealment.”38
Explanation
The use of cohorts or routinely collected data to 
conduct trials might provide opportunities to embed 
automated randomisation or selection and allocation 
algorithms into the cohort or database system to 
allocate participants to trial arms. This process could 
be automated or software embedded within the system 
could communicate with an external randomisation 
system. If such processes are used, authors should 
provide enough details for readers to understand the 
randomisation and allocation concealment processes 




Who generated the random allocation sequence, who 
enrolled participants, and who assigned participants 
to interventions (see CONSORT 2010).8 9
Blinding
Item 11a (unmodified)
If done, who was blinded after assignment to inter-
ventions (eg, participants, care providers, those 
assessing outcomes) and how (see CONSORT 2010).8 9
Item 11b (unmodified)
If relevant, description of the similarity of interventions 
(see CONSORT 2010).8 9
Statistical methods
Item 12a (unmodified)
Statistical methods to compare groups for primary and 


























































































ReseaRch Methods and RepoRting
14 doi: 10.1136/bmj.n857 | BMJ 2021;373:n857 | the bmj
Item 12b (unmodified)
Methods for additional analyses, such as subgroup 
analyses and adjusted analyses (see CONSORT 
2010).8 9
Results
Participant flow (a diagram is strongly 
recommended)
Item 13a (modified)
CONSORT 2010 item: For each group, the numbers of 
participants who were randomly assigned, received 
intended treatment, and were analysed for the primary 
outcome.
Modified CONSORT extension item: For each group, 
the number of participants in the cohort or routinely 
collected database(s) used to conduct the trial and the 
numbers screened for eligibility, randomly assigned, 
offered and accepted interventions (eg, cohort multiple 
randomised controlled trials), received intended 
treatment, and analysed for the primary outcome.
Examples
“We identified the primary care physicians with the 
highest antibiotic prescription rates in Switzerland 
using routinely collected claims data of prescriptions 
of antibiotics and outpatient consultations collected 
by SASIS, a data warehouse company of an umbrella 
organization of Swiss statutory health insurers 
(Santésuisse). These data are collected by over 60 
statutory health insurers covering 64% of the Swiss 
population (5.1 million residents).We included 
among all board certified primary care physicians the 
2900 top antibiotic prescribers (based on prescribed 
defined daily doses [DDD] per 100 consultations in 
the year prior to randomization… Of 2900 randomized 
physicians, all 1450 physicians in the intervention 
group received the evidence-based guidelines and 
first feedback information. Of the 1450 physicians, 
211 (14.6%) opted out later. We used data from 2814 
physicians for the intention-to-treat analysis”21 (fig 
1A).
“Upon receiving permission to contact participants 
from their respective registry site, FHPP [Family 
Health Promotion Project] staff at the University of 
Colorado Cancer Center contacted participants to 
recruit them into the study (n=1,068). Of the 1,068 
subjects contacted, 156 were deemed ineligible and 
280 refused participation for an overall response rate 
of 69% (632 of 912 eligible). The 632 consenting 
participants, representing 533 families, completed 
the baseline survey and were randomized to receive 
either the tailored telephone counseling intervention 
(N=322) or the general mailed intervention (N=310). 
A total of 632 participants were enrolled in the 
FHPP trial. Of the 322 participants randomized to 
the telephone intervention, 306 (95%) received the 
intervention (16 participants could not be reached by 
phone within the allotted time frame per protocol), and 
309 of 310 (>99%) participants in the mailed group 
received the mailed packet. Retention of participants 
over 24 months was greater than 90% overall: 87% 
in the telephone and 94% in the mailed intervention 
group”63 (fig 1B).
Explanation
The number of participants in a cohort or routinely 
collected database(s) and the numbers who were 
screened for eligibility, randomly assigned, offered 
and accepted interventions (eg, cohort multiple 
randomised controlled trials), received the intended 
treatment, and analysed for the primary and secondary 
outcomes should be described. When multiple sources 
of data were linked, potential exclusions because of 
data linkage should be specifically described. If people 
in a cohort or routinely collected database who are not 
included in the trial are observed and their data are 
reported, this should be clearly reported and included 
in the flowchart.
Figure 2 is an example of a flowchart that could be 
used to describe the flow of participants into a cohort 
or routinely collected database and then into the trial. 
Specific components to include depend on the trial 
design and might include the number of participants in 
the cohort or routinely collected database, the number 
who were not screened for eligibility for the trial 
because the recruitment target was met, data linkage 
problems were found, or participants did not consent 
to be contacted for research purposes, for example. 
Elements related to access or use of the intervention 
might also exist. For example, in the design for cohort 
multiple randomised controlled trials, consent for the 
intervention is sought after randomisation, in which 
case the number of participants who gave this consent 
should be reported.
Item 13b (unmodified)
For each group, losses and exclusions after randomisa-
tion, together with reasons (see CONSORT 2010).8 9
Also, for trials using cohorts or routinely collected 
data, losses and exclusions based on data quality or 
linkage problems should be specifically described.
Recruitment
Item 14a (unmodified)
Dates defining the periods of recruitment and 
follow-up.
Example
“A parallel group randomised controlled trial (RCT) 
with 878 participants in the intervention and 1,702 in 
the control group was performed between 2001-2002. 
Briefly, 14 general practitioners with solo practices 
recruited participants for the RCT over a nine-month 
period starting in October 2000. Potential participants 
were identified using complete GP’s patient lists. At 
baseline (2000/2001), eligible study participants 
were at least 60 years old. Eligible individuals received 
the study information letter from their GPs, the PRA 
questionnaire (Probability for Repeated Admission) 
measuring six items of baseline risk status for health 
service use, i.e., person’s age, gender, hospital 
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and diabetes status), and caregiver availability, one 
question on B-ADL [basic activities of daily living] and 
the informed consent form.”64
Explanation
Participants in a cohort or routinely collected database 
are typically followed for an extended period, and 
the starting date of trial recruitment will often differ 
from the start date of data collection in the cohort 
or database. Trials with these types of data might be 
uniquely positioned to obtain long term follow-up 
data. The length of follow-up could be a fixed period 
after randomisation, but in randomised controlled 
trials when the outcome is time to an event, follow-up 
of all participants ends on a specific date. Start and end 
dates for the trial should be given, and the minimum, 
maximum, and median duration of follow-up for trials 
for which the outcome is time to an event should be 
reported. Longer term follow-up subsequent to a trial 
in an ongoing cohort or database, if expected, should 
be explained.
Item 14b (unmodified)
Why the trial ended or stopped (see CONSORT 2010).8 9
Baseline data
Item 15 (unmodified)
A table showing baseline demographic and clinical 
characteristics for each group.
Example
“During the study period, 11,709 patients with 
STEMI [ST-segment elevation myocardial infarction] 
in Sweden and Iceland underwent PCI [percutaneous 
coronary intervention] and were registered in SCAAR 
[Swedish Coronary Angiography and Angioplasty 
Registry]. Of these, 7012 were enrolled in the trial. An 
additional 247 patients were enrolled from the center 
in Denmark, for a total of 7259 patients.… Fifteen 
erroneous enrollments (patients initially reported as 
having STEMI, for whom the diagnosis was changed 
by the operator and no PCI was performed) were 
excluded from the database, leaving 7244 patients 
who underwent randomization. The baseline clinical 
characteristics of all the patients who underwent 
randomization (including patients at all the centers) 
and all the patients who did not undergo randomization 
(including patients at all the centers except the center 
in Denmark) are listed in Table 1.”65
Explanation
A feature of randomised controlled trials using cohorts 
and routinely collected data is that baseline data for 
participants not enrolled in the trial are usually more 
likely to be available. Figure 3 shows the table from 
the example above. Baseline characteristics for eligible 
people from the cohort or routinely collected database 
who were not eligible for the trial because of missing 
data or other administrative reasons, or who declined 
participation, should be reported in the same way, to 
the same extent as the randomised trial participants, 
if possible. Analyses that evaluate differences at trial 
entry between non-participants and those randomised 




For each group, number of participants (denominator) 
included in each analysis and whether the analysis was 
by original assigned groups (see CONSORT 2010).8 9
Outcomes and estimation
Item 17a (unmodified)
For each primary and secondary outcome, results 
for each group, and the estimated effect size and 
its precision (such as 95% confidence interval) (see 
CONSORT 2010).8 9
A B
6613   Physicians assessed for eligibility
1450   Assigned to prescription
              feedback
211   Discontinued intervention
           (opt-out)
1450   Assigned to control
1450   Received prescription
              feedback at least once
1406   Analysed
44   Excluded from analysisa
26   Deregistered from
              healthcare systemb
7   Data error
11   Implausible baseline
         covariatesc
3713   Ineligibile
3713   Did not meet
              inclusion criteria
2900   Randomised
0   Discontinued control (opt-out)
1408   Analysed
42   Excluded from analysisa
20   Deregistered from
              healthcare systemb
7   Data error
15   Implausible baseline
         covariatesc
Fig 1 | Examples of participant flowcharts for checklist item 13a of the CONSORT extension for randomised controlled 
trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE).60 61 (A) Adapted from Hemkens et al21 
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Item 17b (unmodified)
For binary outcomes, presentation of both absolute 




Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, distingui-




All important harms or unintended effects in each 
group (for specific guidance see CONSORT for harms; 




Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses.
Examples
“A number of limitations of the TASTE [Thrombus 
Aspiration in ST-Elevation Myocardial Infarction in 
Scandinavia] trial should be noted. First, the treating 
physician was aware of the group to which the patient 
had been assigned, and that physician entered the 
angiographic variables into the registry; therefore, 
these variables were susceptible to bias. Second, we did 
not adjudicate events and did not review angiograms 
in a blinded fashion. We used all-cause death as the 
primary end point as it is the most stringent end point 
and because of the completeness of the national death 
registries in each participating country. We chose not 
to perform separate adjudication of secondary end 
points both to limit expense and because of the high 
reliability of the SWEDEHEART [Swedish Web System 
for Enhancement and Development of Evidence-
Based Care in Heart Disease Evaluated According to 
Recommended Therapies] registry. A comparison of 
the clinical characteristics and outcomes between the 
patients who underwent randomization and those 
who did not indicates that the two cohorts differed 
significantly in a number of respects. Even when a trial 
uses a population-based registry for enrollment, the 
trial participants cannot be fully representative of the 
complete range of patients.”65
“Awareness of the trial might have itself promoted better 
data recording [in the EHR]. Nevertheless, we observed 
several limitations of the data including, for example, a 
high proportion of patients with unspecified subtype of 
stroke and a smaller number with BP [blood pressure] 
values not recorded during the intervention period. From 
an explanatory perspective, these limitations of the data 
reduce the capacity of the study to provide an accurate 
assessment of intervention efficacy.”37
Explanation
According to CONSORT 2010, identifying and dis-
cussing the potential limitations of a trial is crucial to 
appropriately interpretating the trial results, including 
issues such as potential bias, imprecision, and 
multiplicity of comparisons. Unique characteristics of 
trials using cohorts or routinely collected data might 
be linked to risk of bias and associated problems and, 
therefore, need specific attention in the discussion, 
including issues such as data availability, problems 
with data linkage, data validation, and data quality.54 
The Clinical Trials Transformation Initiative66 has 
similarly identified that problems with the relevance, 
reliability, or reproducibility of data within registries 
or with other routinely collected data can influence the 
conduct and results of the trial.
Generalisability
Item 21 (unmodified)
Generalisability (external validity, applicability) of the 
trial findings.
Example
“A comparison of the clinical characteristics and 
outcomes between the patients who underwent 
Participants in cohort or routinely collected health database
Not assessed for trial eligibility
Recruitment target met
Linking problems
Did not consent to be contacted for








Did not receive allocated intervention (give
  reasons, for example, specific additional
  consent required but not provided, never











Did not receive allocated intervention (give
  reasons, for example, specific additional
  consent required but not provided, never




Lost to follow-up (give reasons)
Discontinued intervention (give reasons)??
??
Lost to follow-up (give reasons)
Discontinued intervention (give reasons)??
??
Analysed
Excluded from analysis (give reasons)??
??
Analysed
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randomization and those who did not indicates that 
the two cohorts differed significantly in a number of 
respects, most notably in mortality at 30 days (2.9% 
among patients who underwent randomization vs. 
10.6% among those who did not). In many cases, 
these differences reflect the exclusion from the trial 
of patients who were ineligible because they were 
unable to provide oral consent. Even when a trial 
uses a population-based registry for enrollment, the 
trial participants cannot be fully representative of the 
complete range of patients.”65
Explanation
Careful attention should be paid to how participants 
in an ongoing cohort or with records in a routinely 
collected database might differ from the population 
targeted by the trial, and these differences and their 
relevance for interpretating the findings of the trial 
should be discussed. Also, any trial design decisions 
related to delivery of the intervention or collection 
of outcomes that were influenced by the use of a 
cohort or routinely collected database should be 
considered. An advantage of many trials conducted 
in cohorts or with routinely collected data is that 
information on participants not included in the trial 
is available. Assessing the degree to which trial 
participants differ from non-participants by reason of 
non-participation can provide readers with insight on 
representativeness. Possible risks to generalisability 




CONSORT 2010 item: Interpretation consistent with 
results, balancing benefits and harms, and considering 
other relevant evidence.
Modified CONSORT extension item: Interpretation 
consistent with results, balancing benefits and harms, 
and considering other relevant evidence, including the 
implications of using data that were not collected to 
answer the specific research question.
Example
“Using the EHR [electronic health record] as a sole 
source of patient data is a limitation. For example, 
the EHR did not capture the patient experience of the 
intervention, including its potential impact on pain 
control, function, and disability. Furthermore, EHR 
data do not provide accurate substance use and mental 
health diagnoses. We did not have prescription or visit 
data from outside health systems.”67
Explanation
Authors should report whether and how the use of 
cohort or routinely collected data might be a limitation 
of the trial. These limitations could include, among 
others, the choice of outcome measures based on 
availability in the cohort or routinely collected 
database, and the quality and accuracy of the outcome 
data. Where possible, results should be compared with 
evidence from similar randomised controlled trials 
with a conventional design, and differences that might 
be related to the use of a cohort or routinely collected 




Registration number and name of trial registry.
Protocol
Item 24 (unmodified)
Where the full trial protocol can be accessed, if 
available.
Example
“This trial used the platform of preexisting health care 
registries for enrollment, randomization, collection 
of data, and follow-up (for further details, see the 
Supplementary Appendix, available at NEJM.org).”60
Explanation
According to CONSORT 2010, trials should be 
registered, and their protocol should be accessible. 
When a trial is being conducted in a cohort or 
routinely collected database, in addition to the 
trial protocol, the authors should ideally provide 
a link to the protocol for the cohort or routinely 
collected database, if separate. This information 
allows interested readers to better understand the 
characteristics of the participants in the cohort or 
database and the data collection methods.
Funding
Item 25 (modified)
CONSORT 2010 item: Sources of funding and other 
support (such as supply of drugs), role of funders.
Fig 3 | Example of table comparing baseline characteristics of participants in the trial 
and those who were not randomised for checklist item 15 of the CONSORT extension 
for randomised controlled trials conducted using cohorts and routinely collected data 
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Modified CONSORT extension item: Sources of 
funding and other support for both the trial and the 
cohort or routinely collected database(s), role of 
funders.
Example
“The registry is financed by the Swedish government 
and the Association of Local Authorities and Regions 
(the public health care provider), and is supported by 
the Swedish Heart Association, the National Board of 
Health and Welfare and the Swedish Heart and Lung 
Foundation. Participating hospitals are not reimbursed 
by the registry and costs of local data entry are borne 
by their internal budget [35, supplement]. The trial 
sponsor was the Karolinska Institutet.”35
Explanation
In addition to providing the funding source for the 
trial, authors should also report any funding sources of 
the cohort or routinely collected data, and if they were 
involved in the use of the cohort or dataset in the trial, 
or in the trial itself.
Conclusions
This extension of the CONSORT reporting guideline 
for trials conducted using cohorts and routinely 
collected data are a minimum set of items to inform 
readers about the trial design and its findings, and 
to support informed decisions about the validity of 
the results of the trial and applicability to readers’ 
research questions. The extension only deals with 
aspects of trial reporting specific to trials conducted 
using cohorts and routinely collected data. When 
reporting a trial using cohorts or routinely collected 
data, authors should look at all items on the CONSORT 
checklist and use this document together with the 
main CONSORT 2010 guidelines. Authors should also 
consult other CONSORT extensions that are relevant to 
their trial design, such as extensions for cluster trials,11 
pragmatic trial designs,13 or others. All are availa-
ble online at www.consort-statement.org/extensions. 
Authors are also encouraged to report any extra 
information, specific to their trial, that would assist 
readers to more easily evaluate the results of the trial 
or to replicate the methods of the trial.
In addition to assisting authors of trial reports, this 
CONSORT extension aims to promote transparency 
and clarity, and to reduce research waste caused 
by poor reporting. We encourage journal editors to 
direct authors of trials conducted using cohorts and 
routinely collected data to use this checklist and to 
document adherence to reporting recommendations as 
a condition of manuscript submission.
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